| Title |
Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic study
|
|---|---|
| Published in |
Clinical Rheumatology, November 2012
|
| DOI | 10.1007/s10067-012-2122-1 |
| Pubmed ID | |
| Authors |
Raoul Bergner, Lena Peters, Verena Schmitt, Christian Löffler |
| Abstract |
Pharmacokinetic data of disease modifying antirheumatic drugs during hemodialysis are limited to sulfasalazine, methotrexate, and cyclosporine. Only respective anecdotal data have been reported on leflunomide. We repeatedly measured teriflunomide (A77-1726), the active metabolite of leflunomide, during standard hemodialysis sessions and calculated teriflunomide clearances in five patients with rheumatoid arthritis (RA) and end-stage renal disease. The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min. Total amount of teriflunomide removed was 5.8-8.8 μg per dialysis session. Dialytic removal of the active metabolite of leflunomide, teriflunomide (A77-1726), is negligible. Leflunomide can be used for RA patients on chronic dialysis without any dosage modification. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 4 | 17% |
| Professor > Associate Professor | 3 | 13% |
| Student > Master | 2 | 9% |
| Lecturer | 1 | 4% |
| Student > Bachelor | 1 | 4% |
| Other | 6 | 26% |
| Unknown | 6 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 48% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
| Psychology | 1 | 4% |
| Neuroscience | 1 | 4% |
| Engineering | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 7 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 July 2013.
All research outputs
#16,835,337
of 25,728,855 outputs
Outputs from Clinical Rheumatology
#2,108
of 3,307 outputs
Outputs of similar age
#185,805
of 286,796 outputs
Outputs of similar age from Clinical Rheumatology
#17
of 26 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,307 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,796 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.